Literature DB >> 10863542

Nitrone inhibition of age-associated oxidative damage.

R A Floyd1, K Hensley.   

Abstract

The mechanistic basis of the neuroprotective activity of the nitrone-based free radical trap PBN (alpha-phenyl-N-tert-butyl nitrone) has been investigated extensively. Key observations exclude its simple mass action spin trapping of free radicals activity as the key mechanism of action. These include: A) the fact that it protects in experimental stroke even if administered several hours after the event and B) the fact that its chronic low-level administration to old experimental animals reverses their age-enhanced susceptibility to stroke even several days after the last dosage. PBN was found to inhibit gene induction in several models including stroke and an LPS-mediated septic shock model. Stoke causes inducible nitric oxide synthase (iNOS) to be expressed. High levels of nitric oxide and peroxynitrite (formed from nitric oxide), produced by iNOS, is particularly neurotoxic. PBN inhibits iNOS induction. Therefore, it seems that prevention of the formation of neurotoxic products is a rational mechanism of action of PBN in the stroke model. There is strong rationale to consider that there is an enhanced propensity for a "smoldering" neuro-inflammatory state in the old brain. Reversal of this state by PBN may explain its action in preventing age-enhanced stroke susceptibility in old experimental animals. Significant new findings underscore the importance of neuro-inflammatory processes in neuronal death or dysfunction in Alzheimer's disease. Neuro-inflammatory processes implicate enhanced signal transduction processes. Strong evidence for this is the enhanced p38 kinase activation in neurons near plaques and tangles of the Alzheimer's brain in contrast to normal aged-matched control brain which did not show p38 activation. In rat primary astrocytes p38 activation by the pro-inflammatory cytokine IL-1 beta, as well as by H2O2, was significantly suppressed by PBN. Mechanistically it was shown that PBN suppresses the amount of reactive oxygen species (ROS) produced in mitochondrial respiration. Much evidence indicates that ROS are signaling molecules and that they also are involved to maintaining brain phosphatases in an inactive state. We argue that finding a specific high affinity site mechanism for the neuroprotective action of PBN is unlikely based on the complexity of the system reflecting ROS generation and signal transduction processes that have apparently evolved to maintain adaptive responses. The promising pharmacological activity of molecules like PBN is not diminished by this however, for only excessive amounts of ROS is considered detrimental. The action of PBN in suppressing signal transduction processes, most likely by suppressing ROS production in mitochondrial respiration, effectively controls excessive oxidative damage and prevents induction of genes that form neurotoxic products.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10863542     DOI: 10.1111/j.1749-6632.2000.tb06189.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  Interleukin-1beta-induced brain injury and neurobehavioral dysfunctions in juvenile rats can be attenuated by alpha-phenyl-n-tert-butyl-nitrone.

Authors:  L W Fan; L T Tien; B Zheng; Y Pang; P G Rhodes; Z Cai
Journal:  Neuroscience       Date:  2010-03-24       Impact factor: 3.590

2.  Age-related changes in nitric oxide synthase in the lateral geniculate nucleus of rats.

Authors:  Seung-Jun Hwang; Youngbuhm Huh
Journal:  J Mol Histol       Date:  2010-05-17       Impact factor: 2.611

3.  Membrane-specific spin trap, 5-dodecylcarbamoyl-5-N-dodecylacetamide-1-pyroline-N-oxide (diC12PO): theoretical, bioorthogonal fluorescence imaging and EPR studies.

Authors:  Colwyn A Headley; Claire N Hoffman; Juliana M Freisen; Yongbin Han; Joseph M Macklin; Jay L Zweier; Antal Rockenbauer; Jeff Kuret; Frederick A Villamena
Journal:  Org Biomol Chem       Date:  2019-07-22       Impact factor: 3.876

Review 4.  Antiaging Therapies, Cognitive Impairment, and Dementia.

Authors:  Devin Wahl; Rozalyn M Anderson; David G Le Couteur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

Review 5.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

6.  Dimethyl cis-2-methyl-3-p-tolyl-isoxazolidine-4,5-dicarboxyl-ate.

Authors:  Mustafa Odabaşoğlu; Hamdi Ozkan; Yılmaz Yıldırır; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-19

7.  Lipophilic beta-cyclodextrin cyclic-nitrone conjugate: synthesis and spin trapping studies.

Authors:  Yongbin Han; Yangping Liu; Antal Rockenbauer; Jay L Zweier; Grégory Durand; Frederick A Villamena
Journal:  J Org Chem       Date:  2009-08-07       Impact factor: 4.354

8.  alpha-Phenyl-n-tert-butyl-nitrone attenuates lipopolysaccharide-induced brain injury and improves neurological reflexes and early sensorimotor behavioral performance in juvenile rats.

Authors:  Lir-Wan Fan; Ruei-Feng Chen; Helen J Mitchell; Rick C S Lin; Kimberly L Simpson; Philip G Rhodes; Zhengwei Cai
Journal:  J Neurosci Res       Date:  2008-12       Impact factor: 4.164

9.  Reactivity of superoxide radical anion with cyclic nitrones: role of intramolecular H-bond and electrostatic effects.

Authors:  Frederick A Villamena; Shijing Xia; John K Merle; Robert Lauricella; Beatrice Tuccio; Christopher M Hadad; Jay L Zweier
Journal:  J Am Chem Soc       Date:  2007-06-12       Impact factor: 15.419

10.  The radical trap 5,5-dimethyl-1-pyrroline N-oxide exerts dose-dependent protection against myocardial ischemia-reperfusion injury through preservation of mitochondrial electron transport.

Authors:  Li Zuo; Yeong-Renn Chen; Levy A Reyes; Hsin-Ling Lee; Chwen-Lih Chen; Frederick A Villamena; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2009-02-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.